
Share
9th August 2023
12:51pm BST

Credit: Getty[/caption]
The mutations in the BRCA1 and BRCA2 genes can leave women, or anyone with a uterus, up to 22 times more likely to develop ovarian cancer and they are six-times more likely to develop breast cancer.
The charity has now warned that there are "potentially thousands" of people who are now missing out on this test.
Victoria Clare, CEO of Ovacome, told The Sun that these tests can provide women and their family "agency” over treatment plans.
“It can give family members who have the gene time to have children sooner if they know they’re going to have preventative surgery,” she said.
Those with the BRCA gene can be offered specific treatment plans if it is detected through this test.
The findings from this study were presented at the British Gynaecological Cancer Society Annual Scientific Meeting in July.
Explore more on these topics: